Tags: Drug.

LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis is in phase III clinical trials and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans.

LGX818_structure.svg
ATC prefix
None
IUPAC name
Methyl [(2S)-1-[4-(3-5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino-2-propanyl]carbamate

Loading...

This page contains content from the copyrighted Wikipedia article "LGX818"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.